Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

被引：879

作者：

Rajkumar, S. Vincent ^{[1
]}

Harousseau, Jean-Luc ^{[2
]}

Durie, Brian ^{[3
]}

Anderson, Kenneth C. ^{[4
]}

Dimopoulos, Meletios ^{[5
]}

Kyle, Robert ^{[1
]}

Blade, Joan ^{[6
]}

Richardson, Paul ^{[4
]}

Orlowski, Robert ^{[7
]}

Siegel, David ^{[8
]}

Jagannath, Sundar ^{[9
]}

Facon, Thierry ^{[10
]}

Avet-Loiseau, Herve ^{[2
]}

Lonial, Sagar ^{[11
]}

Palumbo, Antonio ^{[12
]}

Zonder, Jeffrey ^{[13
]}

Ludwig, Heinz ^{[14
]}

Vesole, David ^{[8
]}

Sezer, Orhan ^{[16
]}

Munshi, Nikhil C. ^{[4
,15
]}

San Miguel, Jesus ^{[17
]}

机构：

[1] Mayo Clin, Rochester, MN 55905 USA

[2] Univ Nantes, Nantes, France

[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Univ Athens, Athens, Greece

[6] Hosp Clin Barcelona, Barcelona, Spain

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] John Theurer Canc Ctr, Hackensack, NJ USA

[9] Mt Sinai Med Ctr, New York, NY 10029 USA

[10] Univ Lille, Lille, France

[11] Emory Clin, Winship Canc Inst, Atlanta, GA 30322 USA

[12] Univ Turin, Turin, Italy

[13] Karmanos Canc Ctr, Detroit, MI USA

[14] Wilhelminen Hosp, Vienna, Austria

[15] Boston Vet Adm Healthcare Syst, W Roxbury, MA USA

[16] Univ Med Ctr, Hamburg, Germany

[17] Univ Hosp, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Salamanca, Spain

来源：

BLOOD | 2011年 / 117卷 / 18期

关键词：

RELAPSED MULTIPLE-MYELOMA; BORTEZOMIB PLUS MELPHALAN; COMPLETE RESPONSE PENALTY; CRITERIA; PREDNISONE;

D O I：

10.1182/blood-2010-10-299487

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

It is essential that there be consistency in the conduct, analysis, and reporting of clinical trial results in myeloma. The goal of the International Myeloma Workshop Consensus Panel 1 was to develop a set of guidelines for the uniform reporting of clinical trial results in myeloma. This paper provides a summary of the current response criteria in myeloma, detailed definitions for patient populations, lines of therapy, and specific endpoints. We propose that future clinical trials in myeloma follow the guidelines for reporting results proposed in this manuscript. (Blood. 2011; 117(18): 4691-4695)

引用

页码：4691 / 4695

页数：5

共 15 条

[1] Clinically relevant end points and new drug approvals for myeloma [J].